Gadopentetate dimeglumine
Magnevist (gadopentetate dimeglumine) is a small molecule pharmaceutical. Gadopentetate dimeglumine was first approved as Magnevist on 1988-06-02.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | 2 | 1 | 2 | 1 | 4 | 10 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | 1 | 1 | — | 4 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | — | 1 | — | 2 |
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Breast diseases | D001941 | N60-N65 | — | — | — | 1 | — | 1 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | 1 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | 1 | ||
| Body image | D001828 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | — | 3 | — | — | 3 |
| Coronary artery disease | D003324 | I25.1 | — | — | 2 | — | 1 | 3 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 2 | — | 1 | 3 |
| Diagnostic imaging | D003952 | — | — | 2 | — | — | 2 | ||
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | 1 | ||
| Renal artery obstruction | D012078 | EFO_1001150 | N28.0 | — | — | 1 | — | — | 1 |
| Carotid stenosis | D016893 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | 1 | — | — | 2 | 3 | |
| Myocardial perfusion imaging | D055414 | — | 1 | — | — | 1 | 2 | ||
| Spinal cord diseases | D013118 | HP_0002196 | G95.9 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | 2 | — | — | — | — | 2 | ||
| Glioma | D005910 | EFO_0000520 | 1 | — | — | — | 1 | 2 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | C67 | 1 | — | — | — | — | 1 | |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | 1 | 1 | |
| Medulloblastoma | D008527 | — | — | — | — | 1 | 1 | ||
| Gliosarcoma | D018316 | — | — | — | — | 1 | 1 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 1 | 1 |
| Ependymoma | D004806 | — | — | — | — | 1 | 1 | ||
| Astrocytoma | D001254 | EFO_0000271 | — | — | — | — | 1 | 1 | |
| Choroid plexus neoplasms | D016545 | EFO_0007206 | — | — | — | — | 1 | 1 | |
| Oligodendroglioma | D009837 | EFO_0000631 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GADOPENTETATE DIMEGLUMINE |
| INN | — |
| Description | Gadopentetate dimeglumine is a gadolinium coordination entity. It has a role as a MRI contrast agent. It contains a gadopentetate. |
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CCN(CC(=O)[O-])CC(=O)O.[Gd+3] |
Identifiers
| PDB | — |
| CAS-ID | 86050-77-3 |
| RxCUI | 25486 |
| ChEMBL ID | CHEMBL1200431 |
| ChEBI ID | — |
| PubChem CID | 55466 |
| DrugBank | DB00789 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,796 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,009 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more